Inhibition of SphK2 can disrupt lipid efflux in hepatocellular carcinoma cells and induce lipotoxic accumulation, suggesting that the SphK2-mTORC2 axis may serve as a novel target for metabolic reprogramming in liver cancer (54). This evidence concerns the gene SPHK2 and hepatocellular carcinoma.